Psilocybin Formulation

Opioid addiction has become a major health crisis that has a massive cost to our society. Existing approaches to breaking addiction have not been successful. A successful approach to break addiction and offering non-addictive pain management products will offer great benefit to society and a successful drug development project for the Company.

The Company’s goal is twofold; to develop psilocybin derived medicines that can break human addictions to Opioids, and non-addictive pain relief that can replace the need for Opioid medicines.

Addiction to Opioids has become a global crisis. For many years, the pharmaceutical Industry has promoted the use of highly addictive pain medications to millions of patients. While these medications have been effective for pain relief, the highly addictive nature of the medications has created a problem with no practical solution. The result has been millions of people becoming addicted to opioid medications, some who have turned to street versions of these drugs to manage their pain. The actions of these pharmaceutical companies have a devastating impact on families and communities. Current solutions proposing free or lower cost opioids is not a solution, society needs practical methods to break addiction, prevent relapse and replace addictive pain management therapies with non-addictive therapies.

The US Council of Economic Advisors estimate the cost to the US economy at more than $500 billion annually, this equates to -almost 4% of GDP. In 2017, more that 70,000 Americans died of drug overdose, with around two-thirds of those deaths linked to opioids. The impact can be measured financially, with massive health care and insurance costs as well as the significant costs of law enforcement. It has been estimated that it will require a large investment, as much as $100 billion, to fully address the crisis.

The Company’s Scientific team is taking theories developed by researchers in the 60’s and 70’s and applying modern approaches to developing novel psychedelics-based formulations. Company researchers believe that its Psilocibyn formulation may also be effective at preventing relapse.